Personalized medicine: Applying 'omics to lung fibrosis

Biomarkers in Medicine

Volumn 6, Issue 4, 2012, Pages 529-540

  Herazo Maya, Jose D ^a   Kaminski, Naftali ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

idiopathic pulmonary fibrosis; MMP7; MUC5B; PCMI; peripheral blood mononuclear cells; personal clinic and molecular mortality prediction index

Indexed keywords

INTERLEUKIN 8; MATRILYSIN; SURFACTANT PROTEIN A;

DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE PREDISPOSITION; EPIGENETICS; FIBROSING ALVEOLITIS; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENOMICS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PERSONALIZED MEDICINE; PREDICTION; PROTEOMICS; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS;

BLOOD PROTEINS; DISEASE SUSCEPTIBILITY; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MATRIX METALLOPROTEINASE 7; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY FIBROSIS; TOMOGRAPHY SCANNERS, X-RAY COMPUTED; TUMOR SUPPRESSOR PROTEINS;

EID: 84865501155     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.38     Document Type: Review

References (102)

1. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 165(2), 277-304 (2002).
2. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 155(1), 242-248 (1997). (Pubitemid 27053171)
3. Baumgartner KB, Samet JM, Coultas DB et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. Am. J. Epidemiol. 152(4), 307-315 (2000). (Pubitemid 30626724)
4. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am. J. Respir. Crit. Care Med. 164(7), 1171-1181 (2001). (Pubitemid 33052246)
5. Marchal-Somme J, Uzunhan Y, Marchand-Adam S et al. Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis. J. Immunol. 176(10), 5735-5739 (2006).
6. Feghali-Bostwick CA, Tsai CG, Valentine VG et al. Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J. Immunol. 179(4), 2592-2599 (2007).
7. Gilani SR, Vuga LJ, Lindell KO et al. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One 5(1), e8959 (2010).
8. Taille C, Grootenboer-Mignot S, Boursier C et al. Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 183(6), 759-766 (2011).
9. *1501 is overrepresented in patients with idiopathic pulmonary fibrosis. PLoS One 6(2), e14715 (2011).
10. Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med. 5(3), e62 (2008).
11. Konigshoff M, Balsara N, Pfaff EM et al. Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One 3(5), e2142 (2008).
12. Vuga LJ, Ben-Yehudah A, Kovkarova-Naumovski E et al. WNT5A is a regulator of fibroblast proliferation and resistance to apoptosis. Am. J. Respir. Cell Mol. Biol. 41(5), 583-589 (2009).
13. Konigshoff M, Kramer M, Balsara N et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J. Clin. Invest. 119(4), 772-787 (2009).
14. Nogee LM, Dunbar AE 3rd, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N. Eng. J. Med. 344(8), 573-579 (2001). □ The first report of surfactant protein C mutations in a patient diagnosed with desquamative interstitial pneumonitis and her newborn daughter diagnosed with nonspecific interstitial pneumonitis. (Pubitemid 32167871)
15. Thomas AQ, Lane K, Phillips J 3rd et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am. J. Respir. Crit. Care Med. 165(9), 1322-1328 (2002). (Pubitemid 34461748)
16. Hodgson U, Pulkkinen V, Dixon M et al. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am. J. Hum. Genet. 79(1), 149-154 (2006). (Pubitemid 43927386)
17. Checa M, Ruiz V, Montano M, Velazquez-Cruz R, Selman M, Pardo A. MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis. Hum. Genet. 124(5), 465-472 (2008).
18. Wang Y, Kuan PJ, Xing C et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am. J. Hum. Genet. 84(1), 52-59 (2009).
19. Seibold MA, Wise AL, Speer MC et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N. Eng. J. Med. 364(16), 1503-1512 (2011). □□ Relatively large study and the first to demonstrate the strong association between the MUC5B single-nucleotide promoter polymorphism in familial interstitial pneumonia and idiopathic pulmonary fibrosis (IPF).
20. Zhang Y, Noth I, Garcia JG, Kaminski N. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N. Eng. J. Med. 364(16), 1576-1577 (2011). □□ This independent case-control study confirmed the MUC5B promoter polymorphism in a cohort of IPF patients evaluated at the University of Pittsburgh and at the University of Chicago.
21. Armanios MY, Chen JJ, Cogan JD et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Eng. J. Med. 356(13), 1317-1326 (2007). □ A key report describing telomerase mutations resulting in short telomeres associated with cases of familial pulmonary fibrosis. (Pubitemid 46513297)
22. Mushiroda T, Wattanapokayakit S, Takahashi A et al. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J. Hum. Genet. 45(10), 654-656 (2008).
23. Sanders YY, Pardo A, Selman M et al. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 39(5), 610-618 (2008).
24. Coward WR, Watts K, Feghali-Bostwick CA, Knox A, Pang L. Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol. Cell. Biol. 29(15), 4325-4339 (2009).
25. Huang SK, Fisher AS, Scruggs AM et al. Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice. Am. J. Pathol. 177(5), 2245-2255 (2010).
26. Coward WR, Watts K, Feghali-Bostwick CA, Jenkins G, Pang L. Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis. Mol. Cell. Biol. 30(12), 2874-2886 (2010).
27. Diaz De Leon A, Cronkhite JT, Katzenstein AL et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One 5(5), e10680 (2010).
28. Rabinovich EI, Kapetanaki MG, Steinfeld I et al. Global methylation patterns in idiopathic pulmonary fibrosis. PLoS One 7(4), e33770 (2012).
29. Fernandez Perez ER, Daniels CE, Schroeder DR et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 137(1), 129-137 (2010).
30. Thabut G, Mal H, Castier Y et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J. Thorac. Cardiovasc. Surg. 126(2), 469-475 (2003). (Pubitemid 37048514)
31. Kass DJ, Kaminski N. Evolving genomic approaches to idiopathic pulmonary fibrosis: moving beyond genes. Clin. Transl. Sci. 4(5), 372-379 (2011).
32. Burke W, Daly M, Garber J et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277(12), 997-1003 (1997). (Pubitemid 27142370)
33. Nelson HD, Huffman LH, Fu R, Harris EL, Force USPST. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U. S. Preventive Services Task Force. Ann. Intern. Med. 143(5), 362-379 (2005).
34. Raghu G, Collard HR, Egan JJ et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidencebased Guidelines for Diagnosis and Management. Am. J. Respir. Crit. Care Med. 183(6), 788-824 (2011).
35. Utz JP, Ryu JH, Douglas WW et al. High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur. Respir. J. 17(2), 175-179 (2001). (Pubitemid 32600574)
36. Lettieri CJ, Veerappan GR, Helman DL, Mulligan CR, Shorr AF. Outcomes and safety of surgical lung biopsy for interstitial lung disease. Chest 127(5), 1600-1605 (2005). (Pubitemid 46222238)
37. Swensen SJ, Aughenbaugh GL, Myers JL. Diffuse lung disease: diagnostic accuracy of CT in patients undergoing surgical biopsy of the lung. Radiology 205(1), 229-234 (1997). (Pubitemid 27415153)
38. Flaherty KR, Thwaite EL, Kazerooni EA et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 58(2), 143-148 (2003). (Pubitemid 36183002)
39. Aziz ZA, Wells AU, Hansell DM et al. HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. Thorax 59(6), 506-511 (2004). (Pubitemid 38797524)
40. Churg A, Muller NL, Flint J, Wright JL. Chronic hypersensitivity pneumonitis. Am. J. Surg. Pathol. 30(2), 201-208 (2006). (Pubitemid 43740189)
41. Kim EA, Lee KS, Johkoh T et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics 22 Spec No: S151-165 (2002). (Pubitemid 41569704)
42. Martinez FJ, Safrin S, Weycker D et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann. Intern. Med. 142(12 Pt 1), 963-967 (2005).
43. Martinez FJ, Flaherty K. Pulmonary function testing in idiopathic interstitial pneumonias. Proc. Am. Thorac. Soc. 3(4), 315-321 (2006). (Pubitemid 43845408)
44. Erbes R, Schaberg T, Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest 111(1), 51-57 (1997). (Pubitemid 27043606)
45. Stephan S, De Castro Pereira CA, Coletta EM, Ferreira RG, Otta JS, Nery LE. Oxygen desaturation during a 4-minute step test: predicting survival in idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 24(1), 70-76 (2007). (Pubitemid 350177775)
46. Shitrit D, Rusanov V, Peled N, Amital A, Fuks L, Kramer MR. The 15-step oximetry test: a reliable tool to identify candidates for lung transplantation among patients with idiopathic pulmonary fibrosis. J. Heart Lung Transplant. 28(4), 328-333 (2009).
47. Lynch DA, Godwin JD, Safrin S et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am. J. Respir. Crit. Care Med. 172(4), 488-493 (2005). (Pubitemid 41117395)
48. Battista G, Zompatori M, Fasano L, Pacilli A, Basile B. Progressive worsening of idiopathic pulmonary fibrosis. High resolution computed tomography (HRCT) study with functional correlations. Radiol. Med. 105(1-2), 2-11 (2003). (Pubitemid 36559771)
49. Flaherty KR, Mumford JA, Murray S et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 168(5), 543-548 (2003). (Pubitemid 37088596)
50. Zappala CJ, Latsi PI, Nicholson AG et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur. Respir. J. 35(4), 830-836 (2010).
51. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 183(4), 431-440 (2011).
52. Du Bois RM, Weycker D, Albera C et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am. J. Respir. Crit. Care Med. 184(12), 1382-1389 (2011).
53. Egan TM, Murray S, Bustami RT et al. Development of the new lung allocation system in the United States. Am. J. Transplant. 6(5 Pt 2), 1212-1227 (2006).
54. Shorr AF, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 122(1), 233-238 (2002). (Pubitemid 34754168)
55. Gries CJ, Mulligan MS, Edelman JD, Raghu G, Curtis JR, Goss CH. Lung allocation score for lung transplantation: impact on disease severity and survival. Chest 132(6), 1954-1961 (2007).
56. Neurohr C, Huppmann P, Thum D et al. Potential functional and survival benefit of double over single lung transplantation for selected patients with idiopathic pulmonary fibrosis. Transpl. Int. 23(9), 887-896 (2010).
57. Lawson WE, Grant SW, Ambrosini V et al. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax 59(11), 977-980 (2004). (Pubitemid 39490784)
58. Lawson WE, Crossno PF, Polosukhin VV et al. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am. J. Physiol. 294(6), L1119-L1126 (2008).
59. Korfei M, Ruppert C, Mahavadi P et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 178(8), 838-846 (2008).
60. Tsakiri KD, Cronkhite JT, Kuan PJ et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc. Natl Acad. Sci. USA 104(18), 7552-7557 (2007). (Pubitemid 47185944)
61. Cronkhite JT, Xing C, Raghu G et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 178(7), 729-737 (2008).
62. Alder JK, Chen JJ, Lancaster L et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc. Natl Acad. Sci. USA 105(35), 13051-13056 (2008).
63. Pulkkinen V, Bruce S, Rintahaka J et al. ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses. FASEB J. 24(4), 1167-1177 (2010).
64. Hutyrova B, Pantelidis P, Drabek J et al. Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 165(2), 148-151 (2002). (Pubitemid 34084448)
65. Zorzetto M, Ferrarotti I, Trisolini R et al. Complement receptor 1 gene polymorphisms are associated with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 168(3), 330-334 (2003). (Pubitemid 36974550)
66. Latsi P, Pantelidis P, Vassilakis D, Sato H, Welsh KI, Du Bois RM. Analysis of IL-12 p40 subunit gene and IFN-gamma G5644A polymorphisms in idiopathic pulmonary fibrosis. Respir. Res. 4, 6 (2003).
67. Zorzetto M, Ferrarotti I, Campo I et al. NOD2/CARD15 gene polymorphisms in idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 22(3), 180-185 (2005). (Pubitemid 41668354)
68. Liu L, Dai HP, Xiao B, Zhang S, Ban CJ, Xin P. [Association of ENA-78, IP-10 and VEGF gene polymorphism with idiopathic pulmonary fibrosis]. Zhonghua Yi Xue Za Zhi 89(38), 2690-2694 (2009).
69. Bournazos S, Bournazou I, Murchison JT et al. Fcgamma receptor IIIb (CD16b) polymorphisms are associated with susceptibility to idiopathic pulmonary fibrosis. Lung 188(6), 475-481 (2010).
70. Ahn MH, Park BL, Lee SH et al. A promoter SNP rs4073T>A in the common allele of the interleukin 8 gene is associated with the development of idiopathic pulmonary fibrosis via the IL-8 protein enhancing mode. Respir. Res. 12, 73 (2011).
71. Martinelli M, Pacilli AM, Rivetti S et al. A role for epidermal growth factor receptor in idiopathic pulmonary fibrosis onset. Mol. Biol. Rep. 38(7), 4613-4617 (2011).
72. Zuo F, Kaminski N, Eugui E et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc. Natl Acad. Sci. USA 99(9), 6292-6297 (2002). □□ This study, the first gene-expression analysis of IPF lungs, demonstrated the upregulation of MMP-7 in fibrotic human lungs and the protection of MMP-7-knockout mice against bleomycin-induced pulmonary fibrosis, showing the importance of this molecule in IPF pathogenesis. (Pubitemid 34493305)
73. Cosgrove GP, Brown KK, Schiemann WP et al. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am. J. Respir. Crit. Care Med. 170(3), 242-251 (2004). (Pubitemid 38971408)
74. Pardo A, Gibson K, Cisneros J et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med. 2(9), e251 (2005).
75. Selman M, Pardo A, Barrera L et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 173(2), 188-198 (2006). (Pubitemid 43187891)
76. Bridges RS, Kass D, Loh K, Glackin C, Borczuk AC, Greenberg S. Gene expression profiling of pulmonary fibrosis identifies Twist1 as an antiapoptotic molecular "rectifier" of growth factor signaling. Am. J. Pathol. 175(6), 2351-2361 (2009).
77. Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM, Feghali-Bostwick CA. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 63(3), 783-794 (2011).
78. Kaminski N, Rosas IO. Gene expression profiling as a window into idiopathic pulmonary fibrosis pathogenesis: can we identify the right target genes? Proc. Am. Thorac. Soc. 3(4), 339-344 (2006). (Pubitemid 43852873)
79. Rosas IO, Kaminski N. When it comes to genes - IPF or NSIP, familial or sporadic - they're all the same. Am. J. Respir. Crit. Care Med. 175(1), 5-6 (2007). (Pubitemid 46115934)
80. Rosas IO, Richards TJ, Konishi K et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 5(4), e93 (2008). □□ This study was the first to establish a combined, genomic targeted, proteomic signature including MMP-1 and MMP-7 to differentiate IPF from controls and other chronic lung diseases.
81. Bazzini AA, Lee MT, Giraldez AJ. Ribosome profiling shows that miR-430 reduces translation before causing mRNA decay in zebrafish. Science 336(6078), 233-237 (2012).
82. Pandit KV, Corcoran D, Yousef H et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 182(2), 220-229 (2010). □□ The investigators discovered the first differentially expressed miRNA signature in IPF lungs and identified a potential mechanism of lung fibrosis pathogenesis by the inhibition of let-7d, one of the downregulated miRNAs in IPF.
83. Liu G, Friggeri A, Yang Y et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J. Exp. Med. 207(8), 1589-1597 (2010).
84. Dai Y, Huang YS, Tang M et al. Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 16(12), 939-946 (2007).
85. Hausler SF, Keller A, Chandran PA et al. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br. J. Cancer. 103(5), 693-700 (2010).
86. Rege TA, Hagood JS. Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses. Biochim. Biophys. Acta 1763(10), 991-999 (2006). (Pubitemid 44466122)
87. Ramirez G, Hagood JS, Sanders Y et al. Absence of Thy-1 results in TGF-beta induced MMP-9 expression and confers a profibrotic phenotype to human lung fibroblasts. Lab. Invest. 91(8), 1206-1218 (2011).
88. Strieter RM, Belperio JA, Keane MP. CXC chemokines in angiogenesis related to pulmonary fibrosis. Chest 122(6 Suppl.), 298S-301S (2002). (Pubitemid 36043017)
89. Selman M, Carrillo G, Estrada A et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One 2(5), e482 (2007).
90. Boon K, Bailey NW, Yang J et al. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One 4(4), e5134 (2009).
91. Collard HR, Moore BB, Flaherty KR et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 176(7), 636-643 (2007). (Pubitemid 47503070)
92. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur. Respir. J. 37(2), 356-363 (2011).
93. Konishi K, Gibson KF, Lindell KO et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 180(2), 167-175 (2009).
94. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415(6870), 389-395 (2002). (Pubitemid 34100944)
95. Herazo JD, Gibson K, Juan-Guardela B et al. Peripheral blood monuclear cells gene expression patterns predict mortality in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 183(A5306), (2011).
96. Eichler GS, Huang S, Ingber DE. Gene Expression Dynamics Inspector (GEDI): for integrative analysis of expression profiles. Bioinformatics 19(17), 2321-2322 (2003). (Pubitemid 37483992)
97. Yokoyama A, Kondo K, Nakajima M et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 11(2), 164-168 (2006). (Pubitemid 43356896)
98. Prasse A, Probst C, Bargagli E et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 179(8), 717-723 (2009).
99. Kinder BW, Brown KK, McCormack FX et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 135(6), 1557-1563 (2009).
100. Moeller A, Gilpin SE, Ask K et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 179(7), 588-594 (2009).
101. Richards TJ, Kaminski N, Baribaud F et al. Peripheral blood proteins predict mortality in idiopathicpulmonary fibrosis. Am. J. Respir. Crit. Care Med. 185(1), 67-76 (2012). □□ By developing a personal clinic and molecular mortality prediction index, which combines clinical and demographic parameters with MMP-7 protein levels in the peripheral blood, this study set the grounds for the use of personalized based approaches for outcome prediction in IPF.
102. Venables WN, Ripley BD. Modern Applied Statistics with S. 4th Edition. Springer, NY, USA (2002).